Psychiatry & Mental Health Clinical Trials

Statistical methods in psychiatry & mental health trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All psychiatry & mental health trials

521 results

• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD): Complete Statistical AnalysisIndependent statistical analysis of Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD): primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 683NCT02709655
• Acute and Residual Effects of Caffeinated Beer: Complete Statistical AnalysisIndependent statistical analysis of Acute and Residual Effects of Caffeinated Beer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515294).Phase 1/2Results postedn = 154NCT00515294
• Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans: Complete Statistical AnalysisIndependent statistical analysis of Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 45NCT02539823
• ADAPTIndependent statistical analysis of ADAPT: Addressing Depression and Pain Together: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01124188).Phase 4Results postedn = 263NCT01124188
• Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living: Complete Statistical AnalysisIndependent statistical analysis of Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 18NCT05956665
• Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder: Complete Statistical AnalysisIndependent statistical analysis of Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 17NCT00601354
• Addressing Cancer-Related Financial Toxicity in North Carolina Oncology Care Settings: Complete Statistical AnalysisIndependent statistical analysis of Addressing Cancer-Related Financial Toxicity in North Carolina Oncology Care Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04931251).Phase NAResults postedn = 205NCT04931251
• ADEPTIndependent statistical analysis of Anhedonia, Development, and Emotions: Phenotyping and Therapeutics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05487885).Phase 4Results postedn = 123NCT05487885
• ADHD-LinkIndependent statistical analysis of Communication to Improve Shared Decision-Making in ADHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02716324).Phase NAResults postedn = 303NCT02716324
• Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: Complete Statistical AnalysisIndependent statistical analysis of Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 9NCT02025855
• Adolescents’ Well-being in Community-based Treatment Versus Residential Treatment: Complete Statistical AnalysisIndependent statistical analysis of Adolescents' Well-being in Community-based Treatment Versus Residential Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06498427).Phase NAResults postedn = 124NCT06498427
• ADORE BRAINIndependent statistical analysis of Brain Health in Midlife: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06640842).Phase NAResults postedn = 24NCT06640842
• Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa: Complete Statistical AnalysisIndependent statistical analysis of Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00310791).Phase 2/3Results postedn = 80NCT00310791
• Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD): Complete Statistical AnalysisIndependent statistical analysis of Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 357NCT00937040
• AEROBICIndependent statistical analysis of Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 60NCT04299308
• AESOPS-T1Independent statistical analysis of Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 555NCT04477304
• Ageing and Health. Spanish Longitudinal Study: Complete Statistical AnalysisIndependent statistical analysis of Ageing and Health. Spanish Longitudinal Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03343886).Phase NAResults postedn = 7,755NCT03343886
• AHIndependent statistical analysis of A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 19NCT03432260
• ALDERIndependent statistical analysis of Anxiety Lowering and Deprescribing Through Emotion Regulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06359314).Phase NAResults postedn = 33NCT06359314
• ALIGN: Aligning Medications With What Matters Most (Demonstration): Complete Statistical AnalysisIndependent statistical analysis of ALIGN: Aligning Medications With What Matters Most (Demonstration): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06335953).Phase NAResults postedn = 474NCT06335953
• ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults: Complete Statistical AnalysisIndependent statistical analysis of ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 31NCT00511836
• AltoidaMLIndependent statistical analysis of Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 548NCT02843529
• AMARANTHComplete statistical analysis of the AMARANTH phase 2/3 trial of lanabecestat in early Alzheimer's disease, including trial design, primary and secondary endpoint results, ANCOVA and mixed-effects methodology, safety, and statistical interpretation.Phase 2/3Results postedn = 2,218NCT02245737
• AMPSIndependent statistical analysis of Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 408NCT04213846
• An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants: Complete Statistical AnalysisIndependent statistical analysis of An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders…Phase NAResults postedn = 13NCT00591565
• An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment: Complete Statistical AnalysisIndependent statistical analysis of An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1Results postedn = 60NCT05051644
• An Alternative Dosing Schedule of Varenicline for Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of An Alternative Dosing Schedule of Varenicline for Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00835900).Phase 2Results postedn = 60NCT00835900
• An App to Reduce Cannabis Use Among Emerging Adults: Complete Statistical AnalysisIndependent statistical analysis of An App to Reduce Cannabis Use Among Emerging Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05824754).Phase NAResults postedn = 122NCT05824754
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder: primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 75NCT00992407
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 4Results postedn = 299NCT00757705
• An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions: Complete Statistical AnalysisIndependent statistical analysis of An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 158NCT04851691
• An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD: Complete Statistical AnalysisIndependent statistical analysis of An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 24NCT05737550
• An Innovative Conversational Agent (Quitbot) for Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of An Innovative Conversational Agent (Quitbot) for Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04308759).Phase NAResults postedn = 1,647NCT04308759
• An Integrated Nutrition Intervention to Promote Healthy Eating Habits for Children With ASD: Complete Statistical AnalysisIndependent statistical analysis of An Integrated Nutrition Intervention to Promote Healthy Eating Habits for Children With ASD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 132NCT05194345
• An Open Label Trial of Bupropion and Naltrexone for Binge Drinking: Complete Statistical AnalysisIndependent statistical analysis of An Open Label Trial of Bupropion and Naltrexone for Binge Drinking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 12NCT02842073
• An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 3NCT01873729
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5): Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 566NCT04820309
• An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00308074).Phase 2Results postedn = 14NCT00308074
• Anti-Diabetic Medications to Fight PD and LBD: Complete Statistical AnalysisIndependent statistical analysis of Anti-Diabetic Medications to Fight PD and LBD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06263673).Phase 4Results postedn = 18NCT06263673
• Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00288366).Phase NAResults postedn = 49NCT00288366
• Antidepressant Effects of TS-161 in Treatment-Resistant Depression: Complete Statistical AnalysisIndependent statistical analysis of Antidepressant Effects of TS-161 in Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04821271).Phase 2Results postedn = 11NCT04821271
• APEX 241Independent statistical analysis of Aripiprazole Open-Label, Safety and Tolerability Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00102518).Phase 3Results postedn = 325NCT00102518
• APSOEMIndependent statistical analysis of Cognitive Function in Elderly Marathon Runners: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01045031).Phase NAResults postedn = 114NCT01045031
• ARIndependent statistical analysis of Augmented Reality Distraction for Reducing Pain in Pediatric Dental Procedures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06954883).Phase NAResults postedn = 60NCT06954883
• ARMSIndependent statistical analysis of Automated Reinforcement Management System (ARMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04656925).Phase NAResults postedn = 12NCT04656925
• ARTISTSIndependent statistical analysis of Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 228NCT03567291
• ASCENDIndependent statistical analysis of Assessing Symptomatic Clinical Episodes in Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03595579).Phase 2Results postedn = 97NCT03595579
• AscenD-LBIndependent statistical analysis of Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 91NCT04001517
• ASDIndependent statistical analysis of Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 64NCT02995408
• Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers: Complete Statistical AnalysisIndependent statistical analysis of Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 63NCT02348203

← All therapeutic areas